Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Inclusion Criteria:

- Written informed consent must be obtained prior to any screening procedures

- Subjects must have recovered from all toxicities related to prior systemic therapy to
grade ≤ 1 (CTCAE v 4.03). Exception to this criterion: subjects with any grade of
alopecia and grade 2 or less neuropathy are allowed to enter the study

- ECOG performance status (PS) of 0 or 1

Exclusion Criteria:

- Subjects with unresectable or metastatic disease, positive microscopic margins on the
pathology report, and/or gross disease remaining at the time of surgery

- Subjects who received neoadjuvant chemotherapy or neoadjuvant radiotherapy

- Presence or history of a malignant disease, other than the resected NSCLC, that has
been diagnosed and/or required therapy within the past 3 years Exceptions to this
exclusion include the following: completely resected basal cell and squamous cell skin
cancers, completely resected carcinoma in situ of any type and hormonal maintenance
for breast and prostate cancer > 3 years.

- Known active or recurrent hepatic disorder including cirrhosis, hepatitis B and C
(positive or indeterminate central laboratory results)

- Subjects must be evaluated for tuberculosis as per local treatment guidelines or
clinical practice. Subjects with active tuberculosis are not eligible.

- Subjects with suspected or proven immunocompromised state as described in the protocol

- Live and attenuated vaccination within 3 months prior to first dose of study drug
(e.g. MMR, Yellow Fever, Rotavirus, Smallpox, etc.).